Taiwan
Primo Biotechnology 普瑞默生技 is a dynamic newcomer in the Taiwanese radiopharmaceutical landscape, established in 2023. With their slogan, "Future in Precision｜精準守護 你的未來," they aim to transform healthcare precision through molecular imaging technologies. Founded by Prof. Ya-Yao Huang and Dr. Joe Yeh, the team brings extensive experience in radiopharmaceutical discovery and development, particularly in clinical introduction and IND submission processes.
The company targets the Biotechnology and Pharmaceutical industries, focusing on full-spectrum clinical development of radiotheranostics within Taiwan. Primo manages activities from pre-clinical studies to commercialization and distribution, thereby offering a comprehensive service in the radiopharmaceutical space.
In its recent financial milestone, Primo Biotechnology secured a $7.52M Series A investment as of 01 July 2025. This capital will enhance their ability to innovate and expand operations, marking them as a promising candidate for further investor attention.
